Found 46 results
Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.
Jiao W, Atwal G, Polak P, Karlic R, Cuppen E, Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N et al..  2020.  A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns.. Nat Commun. 11(1):728.
Vlachostergios PJ, Faltas BM, Carlo MI, Nassar AH, Alaiwi SAbou, Sonpavde G.  2020.  The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.. Cancer Treat Res Commun. 23:100165.
Sfakianos JP, Daza J, Hu Y, Anastos H, Bryant G, Bareja R, Badani KK, Galsky MD, Elemento O, Faltas BM et al..  2020.  Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers.. Nat Commun. 11(1):2540.
Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA, Flaig TW, DeGraff DJ, Christensen E, Woolbright BL, McConkey DJ, Dyrskjøt L.  2020.  Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.. Nat Rev Urol.
Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, Matin SF, Roupret M, Sfakianos JP, Shariat SF et al..  2020.  Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.. Eur Urol.
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium.  2020.  Pan-cancer analysis of whole genomes.. Nature. 578(7793):82-93.
Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JMiguel, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al..  2019.  Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.. JCO Precis Oncol. 3
Grivas P, Lalani A-KA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J et al..  2019.  Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.. Eur Urol Oncol.
Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al..  2019.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3
Vlachostergios PJ, Faltas BM.  2019.  The molecular limitations of biomarker research in bladder cancer.. World J Urol. 37(5):837-848.
Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..  2019.  Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.
Persi E, Prandi D, Wolf YI, Pozniak Y, Barnabas GD, Levanon K, Barshack I, Barbieri C, Gasperini P, Beltran H et al..  2019.  Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues.. Proc Natl Acad Sci U S A. 116(34):16987-16996.
Shohdy KS, Vlachostergios PJ, Abdel-Malek RR, Faltas BM.  2019.  Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma.. Expert Opin Ther Targets. 23(2):83-86.
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J et al..  2019.  Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.. Nat Commun. 10(1):2977.